INSIDE THE AI DRUG DISCOVERY ARMS RACE

Summary from the TLDR AI newsletter

AI is rapidly transforming drug discovery, with biologics developers securing $1.6B in 2024 funding, indicating an expanding focus beyond small molecules. M&A activity in AI drug discovery is surging, with major big pharma players acquiring startups and bolstering in-house AI capabilities. This reflects a growing urgency to integrate AI in drug R&D to reduce costs and accelerate development.